Corteria Pharmaceuticals has launched the first stage of clinical trials to assess the efficacy of their CRF2 activator, COR-1167, specifically targeting the progression of cardiac insufficiency.
Levocetirizine is a small, powerful drug that works as an H1 receptor antagonist to treat various allergies, including respiratory issues, dermatitis, and eczema.
Intravacc, a globally recognized pioneer in the field of translational research as well as the creation of vaccines for both prevention and treatment, has shared encouraging results from initial human trials of Avacc 10.
Bioequivalence is a pharmacological term used to describe the similarity in the pharmacokinetic profiles of two drug products, usually a brand-name drug and a generic drug.
Aptamer Sciences Submits New Drug Application for Groundbreaking Hepatocellular Carcinoma Therapy AST-201: A Potential Solution for Unmet Treatment Requirements.
Bioavailability refers to the extent and rate at which the active ingredient of a drug or nutrient is absorbed into the circulation and becomes available at the site of action within the body.
Apogee Therapeutics has initiated dosing of initial volunteers in a Phase 1 study of their new extended-duration IL-4Rα antibody, APG808, aimed at managing Chronic Obstructive Pulmonary Disease (COPD) and various inflammatory conditions.
Regeneron Pharmaceuticals, Inc. has declared the receipt of Complete Response Letters from the U.S. Food and Drug Administration concerning their submitted Biologics License Application for the drug odronextamab.